Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

被引：0
|
作者：
R. de Haan
E. van Werkhoven
M.M. van den Heuvel
H. M. U. Peulen
G. S. Sonke
P. Elkhuizen
M. W. M. van den Brekel
M. E. T. Tesselaar
C. Vens
J. H. M. Schellens
B. van Triest
M. Verheij
机构：
[1] Department of Radiation Oncology,Department of Biometrics
[2] The Netherlands Cancer Institute,Department of Thoracic Oncology
[3] The Netherlands Cancer Institute,Department of Medical Oncology
[4] The Netherlands Cancer Institute,Department of Head and Neck Surgery and Oncology
[5] The Netherlands Cancer Institute,Division of Cell Biology
[6] The Netherlands Cancer Institute,Division of Pharmacology
[7] The Netherlands Cancer Institute,Department of Pharmaceutical Sciences
[8] The Netherlands Cancer Institute,undefined
[9] Utrecht University,undefined
来源：
BMC Cancer | / 19卷
关键词：
Radiotherapy; Radiosensitisation; Olaparib; PARP inhibitor; Phase 1; Dose escalation; TITE-CRM; Dose limiting toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
    de Haan, R.
    van Werkhoven, E.
    van den Heuvel, M. M.
    Peulen, H. M. U.
    Sonke, G. S.
    Elkhuizen, P.
    van den Brekel, M. W. M.
    Tesselaar, M. E. T.
    Vens, C.
    Schellens, J. H. M.
    van Triest, B.
    Verheij, M.
    BMC CANCER, 2019, 19 (01)
  • [2] Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites
    Verheij, M.
    De Haan, R.
    Van Triest, B.
    Schellens, J.
    Van den Brekel, M.
    Verhagen, C.
    Vens, C.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S138 - S138
  • [3] Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts)
    Michalarea, V.
    Lopez, J.
    Lorente, D.
    Carreira, S.
    Hassam, H.
    Parmar, M.
    Turner, A.
    Hall, E.
    Fandos, S. Serrano
    Decordova, S.
    Swales, K.
    Ruddle, R.
    Raynaud, F.
    Tunariu, N.
    Stephens, C. M.
    Molife, L. R.
    Banerji, U.
    Plummer, R.
    De Bono, J.
    Yap, T. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S68 - S68
  • [4] Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
    Lampert, Erika J.
    Zimmer, Alexandra
    Padget, Michelle
    Cimino-Mathews, Ashley
    Nair, Jayakumar R.
    Liu, Yingmiao
    Swisher, Elizabeth M.
    Hodge, James W.
    Nixon, Andrew B.
    Nichols, Erin
    Bagheri, Mohammad H.
    Levy, Elliott
    Radke, Marc R.
    Lipkowitz, Stanley
    Annunziata, Christina M.
    Taube, Janis M.
    Steinberg, Seth M.
    Lee, Jung-Min
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4268 - 4279
  • [5] Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
    Do, Khanh T.
    Kochupurakkal, Bose
    Kelland, Sarah
    de Jonge, Adrienne
    Hedglin, Jennifer
    Powers, Allison
    Quinn, Nicholas
    Gannon, Courtney
    Vuong, Loan
    Parmar, Kalindi
    Lazaro, Jean-Bernard
    D'Andrea, Alan D.
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4710 - 4716
  • [6] A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
    Tuli, R.
    Shiao, S. L.
    Nissen, N.
    Tighiouart, M.
    Kim, S.
    Osipov, A.
    Bryant, M.
    Ristow, L.
    Placencio-Hickok, V. R.
    Hoffman, D.
    Rokhsar, S.
    Scher, K.
    Klempner, S. J.
    Noe, P.
    Davis, M. J.
    Wachsman, A.
    Lo, S.
    Jamil, L.
    Sandler, H.
    Piantadosi, S.
    Hendifar, A.
    EBIOMEDICINE, 2019, 40 : 375 - 381
  • [7] ENCOURAGING DATA FROM A PHASE I STUDY OF THE FIRST ORAL PARP INHIBITOR OLAPARIB IN JAPANESE PATIENTS WITH SOLID TUMOURS
    Yamamoto, N.
    Nokihara, H.
    Yamada, Y.
    Goto, Y.
    Tanioka, M.
    Shibata, T.
    Yamada, K.
    Asahina, H.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 176 - 176
  • [8] A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses
    Zimmer, Alexandra S.
    Nichols, Erin
    Cimino-Mathews, Ashley
    Peer, Cody
    Cao, Liang
    Lee, Min-Jung
    Kohn, Elise C.
    Annunziata, Christina M.
    Lipkowitz, Stanley
    Trepel, Jane B.
    Sharma, Rajni
    Mikkilineni, Lekha
    Gatti-Mays, Margaret
    Figg, William D.
    Houston, Nicole D.
    Lee, Jung-Min
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [9] Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
    Fanucci, Kristina
    Pilat, Mary Jo
    Shyr, Derek
    Shyr, Yu
    Boerner, Scott
    Li, Jing
    Durecki, Diane
    Drappatz, Jan
    Puduvalli, Vinay
    Lieberman, Frank Scott
    Gonzalez, Javier
    Giglio, Pierre
    Ivy, S. Percy
    Bindra, Ranjit S.
    Omuro, Antonio
    LoRusso, Patricia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (02): : 192 - 201
  • [10] A study into the pharmacodynamic biomarker effects of olaparib (PARP Inhibitor) degarelix (GnRH antagonist) given prior to radical prostatectomy (RP) CANCAP03.
    Pacey, Simon
    Linch, Mark David
    Kynaston, Howard
    Warren, Anne
    Freeman, Alex
    Tysoe, Ruth
    Shaw, Greg
    Narahari, Krishna
    Kumar, Satish
    Martin, Henno
    Kularatne, Bihani
    Gnanapragasam, Vincent
    Davies, Barry
    Khan, Josephine
    Bratt, Ola
    Dev, Harveer
    Massie, Charles
    Shah, Nimish
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345